This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Tops Q3 Earnings Estimates, Sales In Line
by Zacks Equity Research
Pfizer (PFE) beat expectations for earnings while delivering in-line revenues in Q3. It raised adjusted earnings guidance while tightening the revenue expectations for 2017.
Is Aerie (AERI) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Aerie Pharmaceuticals (AERI) is looking solid on strong prospects of its lead candidate, Rhopressa. We expect investors to focus on further pipeline updates on the third-quarter call.
What's in the Cards for PFE, INCY and ACOR in Q3 Earnings?
by Zacks Equity Research
The third-quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players like Pfizer, Incyte and Acorda follow suit.
Pharma Stock Roundup: Lilly Tops on All Fronts, Mixed Results from Bristol-Myers
by Arpita Dutt
It was all about earnings this week with companies like Eli Lilly (LLY), Bristol-Myers Squibb and Novartis reporting third quarter results.
The Zacks Analyst Blog Highlights: Merck, Pfizer, Aetna and Electronic Arts
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Pfizer, Aetna and Electronic Arts
Glaxo (GSK) Q3 Earnings Beat, Revenues In Line, Shares Down
by Zacks Equity Research
Glaxo's (GSK) Q3 earnings top estimates while revenues match the same. However, the bottom was flat at constant exchange rates (CER).
Merck vs. Pfizer: Which is Better Ahead of Q3 Earnings?
by Swarup Gupta
With Merck and Pfizer scheduled to report on Oct 27 and Oct 31, respectively this may be a good time to consider which of these is a better stock.
Is a Beat Likely for Pfizer (PFE) This Earnings Season?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive sales in Q3, genericization of key drugs, pricing pressure and rising competition will hurt sales.
Corning (GLW) Beats Q3 Earnings on High Gorilla Glass Demand
by Zacks Equity Research
Corning's (GLW) third-quarter results benefited from the revenue upside driven by strong sales of Gorilla Glass and fiber products.
Can AbbVie (ABBV) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q3.
Healthcare ETFs Set to Soar as Q3 Earnings Unfold
by Sweta Killa
With earnings surprises well in the cards, healthcare ETFs are set to soar.
Will Merck (MRK) Keep the Earnings Streak Alive in Q3?
by Zacks Equity Research
Merck's (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q3. However, headwinds remain in the form genericization of key drugs and increasing competition.
Healthcare ETF (VHT) Hits New 52-Week High
by Zacks Equity Research
Healthcare ETF hits a new 52-week high amid strong earnings and talks of bipartisan deal.
Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?
by Zacks Equity Research
The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .
Healthcare ETFs Head to Head: XLV vs. VHT
by Zacks Equity Research
Head to head comparison of two Healthcare ETFs, XLV and VHT.
Healthcare ETFs in Focus on Johnson & Johnson Q3 Earnings
by Zacks Equity Research
Johnson & Johnson reports Q3 results with both revenues and EPS beating estimates.
Conatus Entrusts Keith W. Marshall With Key Management Roles
by Zacks Equity Research
Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.
What to Expect from Big Pharmas After J&J's Solid Q3 Results?
by Zacks Equity Research
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.
Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?
by Zacks Equity Research
At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.
Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Aerie (AERI) Up on FDA Review Committee Result for Rhopressa
by Zacks Equity Research
Shares of Aerie Pharmaceuticals, Inc. (AERI) have moved up 15.8% in the last week on positive news for its lead drug, Rhopressa.
J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales
by Zacks Equity Research
J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
by Zacks Equity Research
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks
by Arpita Dutt
Innovation, mergers and acquisitions (M&As), strong results, product approvals and positive data flow should act as catalysts for pharma and biotech stocks.
J&J's Psoriasis Drug Stelara Gets FDA Nod for Adolescent Use
by Zacks Equity Research
Johnson & Johnson (JNJ) announced approval of label expansion for its plaque psoriasis drug, Stelara, to include adolescent patients.